Activated Protein C Does Not Alleviate the Course of Systemic Inflammation in the APCAP Trial

Lea Kyhälä, Panu Mentula, Leena Kylänpää, Eeva Moilanen, Pauli Puolakkainen, Ville Pettilä, and Heikki Repo

1 Department of Surgery, Helsinki University Central Hospital, 00029 Helsinki, Finland
2 The Immunopharmacology Research Group, University of Tampere School of Medicine and Tampere University Hospital, 33521 Tampere, Finland
3 Intensive Care Units, Department of Anesthesia and Intensive Care Medicine, Helsinki University Central Hospital, 00029 Helsinki, Finland
4 Department of Medicine, University of Helsinki, 00029 Helsinki, Finland

Correspondence should be addressed to Lea Kyhälä, lea.kyhala@hus.fi

Received 24 November 2011; Accepted 20 February 2012

1. Introduction

Acute pancreatitis (AP), a common cause of abdominal pain, is usually a mild, self-limited disease. However 25% of the patients suffer from severe AP (SAP) [1], and 20% of SAP patients die, [2], mostly due to the development of multiple organ dysfunction [3]. Systemic inflammation, typical of AP, is considered to contribute to the development of organ dysfunction. It is characterized by (i) an increase in circulating levels of proinflammatory cytokines [4, 5], anti-inflammatory cytokines [6–9], and soluble E-selectin (sE-selectin) [10–12], a marker of activation of the vascular endothelium, (ii) occurrence of activated phagocytes in the circulation [13, 14], and (iii) a decrease in HLA-DR expression on blood monocytes [9, 13, 15, 16], denoting the development of immune suppression.

Activated protein C (APC) is a plasma serine protease with effects on coagulation, apoptosis, and inflammation [17]. APC acts as an endogenous anticoagulant that promotes fibrinolysis and inhibits thrombosis. Protein C, an inactive precursor, is converted to activate protein C by thrombin-thrombomodulin complex on endothelium [18]. This process is accelerated in the presence of endothelial PC receptor (EPCR) [19]. APC inactivates the procoagulation factor Va and VIIIa shutting down the coagulation pathway. APC also inactivates plasminogen activator inhibitor, which results in increased fibrinolysis [18].

APC also has cytoprotective effects such as anti-inflammatory, antiapoptotic, and endothelial barrier protection effects [20].

Proinflammatory cytokines upregulate thrombin formation and downregulate the host’s antithrombotic mechanisms, in particular the protein C (PC) pathway reviewed in [21]. Deficiency of PC and decreased generation of activated PC (APC), the major endogenous anticoagulant in man, associate with the development of organ dysfunction in AP
2. Subjects and Methods

2.1. Patients and Healthy Subjects. We previously conducted a randomized study of APC in SAP patients [24]. In brief, this prospective randomized double-blind study included analysis of 32 patients with SAP in the tertiary care unit at the Helsinki University Central Hospital between June 2003 and August 2007. The inclusion criteria were (1) admitted to hospital 96 h from the onset of pain, (2) a 3-fold increase in serum amylase (IU/L) over normal upper range, and on serum levels of procalcitonin (PCT), a marker of systemic inflammation used in clinical decision making.

We previously conducted a randomized trial previously [22]. In patients with sepsis human recombinant APC shortened the duration of respiratory dysfunction and accelerated the reversal of shock [23]. We studied in a randomized trial patients with severe AP and found no differences in the evolution of multiorgan dysfunction between APC and placebo groups [24]. However, the effects of APC on inflammatory markers in patients with SAP have not been studied in a randomized controlled trial previously.

Accordingly, we aimed to determine the effects of the APC intervention on plasma levels of proinflammatory (IL-8), pro-/anti-inflammatory (IL-6) and anti-inflammatory (IL-10, IL-1ra) cytokines and sE-selectin, on activation markers of blood monocytes (CD14, CD11b, CD62L) and neutrophils (CD11b, CD62L), on levels of monocyte cell-surface expression of HLA-DR, a marker of immune suppression, and on serum levels of procalcitonin (PCT), a marker of systemic inflammation used in clinical decision making.

Accordingly, we aimed to determine the effects of the APC intervention on plasma levels of proinflammatory (IL-8), pro-/anti-inflammatory (IL-6) and anti-inflammatory (IL-10, IL-1ra) cytokines and sE-selectin, on activation markers of blood monocytes (CD14, CD11b, CD62L) and neutrophils (CD11b, CD62L), on levels of monocyte cell-surface expression of HLA-DR, a marker of immune suppression, and on serum levels of procalcitonin (PCT), a marker of systemic inflammation used in clinical decision making.

2.2. Blood Samples. When a patient fulfilled the inclusion criteria we collected peripheral blood samples for determination of cell markers of inflammation by venipuncture for the first time. Then the patients were randomized. After that follow-up samples were collected in the morning of the third, fifth, seventh, and 14th day. Blood samples for flow cytometry and for plasma measurements were anticoagulated with pyrogen-free acid-citrate dextrose (ACD). Blood samples were immediately cooled in an ice-cold water bath and kept at 0°C until stained for flow cytometry. The plasma was separated by centrifugation at +4°C and stored at −70°C until concentrations of cytokines and sE-selectin were determined. Blood samples for determination of serum PCT were collected concurrently.

2.3. Analysis of Soluble Markers. The concentrations of IL-6, IL-8, IL-10, IL-1Ra, and E-selectin in plasma samples were determined by enzyme immunoassay (EIA) by using commercial reagents (IL-6 and IL-10: PeliPair ELISA, Sanquin, Amsterdam, the Netherlands; IL-8: Opt EIA, BD Biosciences, Erembodegem, Belgium; IL-1Ra: Duo Set ELISA, R&D Systems Europe Ltd, Abingdon, UK; E-Selectin: ELISA, HyCult Biotechnology, Uden, The Netherlands). The detection limits and intra-assay and interassay coefficients of variation (CV%) were as follows: IL-6: 0.3 pg/mL, 3.6% and 5.4%; IL-8: 1.6 pg/mL, 3.5%, 3.4%; IL-10: 0.3 pg/mL, 3.7%, 5.9%; IL-1Ra: 10 pg/mL, 4.2%, 5.2%; E-selectin 20.5 pg/mL, 3.5%, 6.9%.

Procalcitonin (PCT) was measured using ADVIA Centaur XP immunoassay system with ADVIA Centaur BRAHMS PCT assay. Assay is a sandwich chemiluminescent immunoassay using monoclonal antibody to fluororescin covalently linked to paramagnetic particles and two antibodies to procalcitonin labelled with fluorescein. According to the manufacturer, the within-run precision of the method is 4.3%, 1.5%, and 1.5% for PCT at 0.2, 0.97, and 65.9 μg/L, respectively. The between-run precision is 8.5%, 2.1%, and 7.2% for the respective concentrations. The limit of detection for the assay is 0.04 μg/L and dilution point 75 μg/L.

2.4. Analysis of Cell Surface Markers

Monoclonal Antibodies and Flow Cytometry. Monocyte expression of CD14, CD11b, CD62L and HLA-DR and neutrophil expression of CD62L and CD11b were determined using whole blood flow cytometry, as described previously [9, 13]. Monoclonal antibodies (mAbs) were as follows: phycoerythrin (PE) and fluororescin isothiocyanate (FITC) conjugates of anti-CD14 mAb (IgG2b, clone MFP9), PE conjugates of anti-HLA-DR mAb (IgG2a, clone L243), anti CD11b mAb (IgG2a, clone D12) and control mouse IgG2a, mAb, and FITC conjugate of anti-CD62L mAb (IgG2a, clone SK11). All reagents were purchased from Becton Dickinson (San Jose, CA, USA). Staining of aliquots of the whole blood sample at 0°C for flow cytometry was carried out as described previously [9, 13]. Data acquisition and analyses were done by a FACSCalibur flow cytometer and Cell Quest software (BD Sciences, San Jose, CA). Neutrophils were identified by the light scattering properties and monocytes by the clonal marker CD14. Monocyte HLA-DR expression was determined as the proportion of HLA-DR positive monocytes, as described earlier [13]. Fluorescence intensity is presented as relative fluorescence units (RFUs).

2.5. Statistical Analysis. The primary end point of the randomized study was the change in SOFA score. The sample...
size for the study was determined according to the primary end point: there would be three-point difference in change of SOFA score between the groups (with $P < 0.05$ and a power of 80%) [24]. Values are given as medians and ranges. Comparisons of marker levels between the two groups (the APC group and the placebo group) were performed by the Mann-Whitney U-test. In case of repeated sampling from the healthy volunteers mean data was used to get one value for each person and after that median was used. The Wilcoxon signed-rank test was used in comparisons of repeated measurements. A difference with a $P$-value of less than 0.05 was considered to be statistically significant. Statistical analysis was performed using SPSS19.0 statistical software (Chicago, Illinois).

3. Results

3.1. Patients. Characteristics of the 32 SAP patients are given in Table 1. All except one of the patients were admitted to the ICU. The time before patients were admitted to the ICU was 1.0 days (0–3 days) in APC group and 2.0 (1–2 days) in the placebo group ($P = 0.642$). In the APC group there were two nonsurvivors: one after receiving 13 hours of APC infusion and the other one having a laparotomy after 41 hours of APC infusion.

3.2. Soluble Markers. Plasma concentrations of proinflammatory cytokine IL-8 of all patients decreased during the first five days after the admission to hospital (day 0: 264 pg/mL versus day 5: 110 pg/mL, $P = 0.001$). The APC treatment had no significant effect on the changes in IL-8 concentrations during the follow-up period (Table 2).

Plasma concentrations of pro-/anti-inflammatory cytokines IL-10 and IL-1Ra of all patients decreased during the first five days of the follow-up time (IL-6 day 0: 670 pg/mL versus day 5: 215 pg/mL, $P = 0.001$; IL-10 day 0: 12.7 pg/mL versus day 5: 11.3 pg/mL, $P = 0.001$; IL-1Ra day 0: 2890 pg/mL versus day 5: 1250 pg/mL, $P = 0.007$). The APC treatment did not have any significant effect on the changes in IL-6, IL-10, and IL-1Ra concentrations during the first five or 14 days of follow-up time (Table 2).

Plasma concentrations of soluble E-selectin of all patients decreased along the course of the disease (day 0: 45.5 ng/mL versus day 5: 38.2 ng/mL, $P = 0.031$), but the APC treatment did not have any significant effect on the changes in concentrations of sE-selectin (Table 2).

There were no significant changes in serum concentrations of procalcitonin of all patients during the first five days (day 0: 0.97 ng/mL versus day 5: 0.66 ng/mL, $P = 0.487$), and administration of APC did not alter the changes in PCT concentrations (Table 2).

3.3. Cell Surface Markers. As a marker of immune suppression monocyte HLA-DR expression of all patients was not altered significantly during the first five days of follow-up period (day 0: 54% versus day 5: 58%, $P = 0.316$). Neither had the APC infusion any effect on the HLA-DR expression (Table 3).

The cell surface expressions of CD11b, CD14, and CD62L were measured as markers of activation of monocytes. The cell surface expression of CD11b, CD14, and CD62L on monocytes of all patients was downregulated during the first five days (MoCD11b day 0: 291 RU versus day 5: 168 RU, $P = 0.001$; MoCD14 day 0: 168 RU versus day 5: 150 RU, $P = 0.028$; MoCD62L day 0: 217 RU versus day 5: 135 RU, $P = 0.001$). The expression of CD11b, CD14, and CD62L did not differ significantly between the placebo and the APC-treatment group (Table 3).

---

### Table 1: Characteristics of patients.

|                      | Activated protein C | Placebo |
|----------------------|---------------------|---------|
| No. of patients      | 16                  | 16      |
| Male/female          | 16/0                | 15/1    |
| Etiology of SAP      | -Alcohol/biliary    |         |
| Age (years)          | 44 (34–36)          | 47 (19–59) |
| SOFA score on admission | 8.0 (3–13)        | 8.5 (3–15) |
| ICU stay (days)      | 10.0 (2–43)         | 11.0 (0–31) |

*Values are median (range).
Table 2: The changes in concentrations of soluble inflammation markers between days 0–5 and 0–14. Median (range).

| Marker         | APC baseline | Placebo baseline | P-value | APC change 0–5 d | Placebo change 0–5 d | P-value | APC change 0–14 d | Placebo change 0–14 d | P-value |
|----------------|--------------|------------------|---------|------------------|----------------------|---------|------------------|-----------------------|---------|
|                | n = 16       | n = 16           |         | n = 14           | n = 13               |         | n = 11           | n = 11                 |         |
| IL-8, pg/mL    | 286 (56.4–1760) | 245 (41.5–1750)  | 0.867   | −72.3 (−1630–60.8) | −39.5 (−275–470)     | 0.159   | −84.9 (−266–263)  | −132 (−1280–50.4)      | 0.270   |
| IL-6, pg/mL    | 798 (93–7190) | 643 (235–41800)  | 1.000   | −377 (−1350–1090) | −517 (−41600–182)    | 0.159   | (−1550–979) | (−41700–388) | 0.288 |
| IL-1ra, pg/mL  | 4480 (143–107000) | 2870 (656–12400) | 0.590   | −2210 (−20500–2160) | −1480 (−1150–6380)   | 0.627   | −7850 (−7850–3950) | −750 (−3890–2240)      | 0.243   |
| IL-10, pg/mL   | 13.7 (2.78–367) | 10.8 (4.17–145)  | 0.724   | −5.51 (−28.9–6.04) | −6.72 (−137–28.1)    | 0.438   | −33.2 (−33.2–72.1) | −6.70 (−139–77.0)      | 0.898   |
| sE-selectin, ng/mL | 41.4 (25.3–195) | 86.1 (19.0–192)  | 0.445   | 0.06 (−139–20.0)   | −40.5 (−135–16.9)    | 0.099   | 0.100 (−143–14.4) | −45.6 (−144–8.70)      | 0.270   |
| PCT, ng/mL     | 1.03 (0.12–8.33) | 0.75 (0.18–3.96) | 0.880   | 0.18 (−7.53–3.47)  | −0.21 (−1.91–1.62)   | 0.590   | 0.130 (−4.66–3.96) | −0.270 (−3.30–2.09)    | 0.918   |

1 n = 14, 2 n = 15, 3 n = 11, 4 n = 10, 5 n = 12, 6 n = 10.
d: day; IL: interleukin; PCT: procalcitonin.
P-values are calculated for differences between the two groups in changes from baseline.
| Marker median, range of healthy reference subjects, n | APC baseline n = 16 | Placebo baseline n = 15 | P-value | APC change 0–5 d n = 14 | Placebo change 0–5 d n = 12 | P-value | APC change 0–14 d n = 11 | Placebo change 0–14 d n = 10 | P-value |
|---------------------------------------------------|----------------------|------------------------|---------|-------------------------|----------------------------|---------|--------------------------|-----------------------------|---------|
| MoHLA-DR, % 95.0 (42–99), n = 64                   | 54.0 (13–73)         | 44.0 (26–75)           | 0.599   | 10.0 (-21–30)           | 1.00 (-50–22)              | 0.173   | 13.0 (-18–37)            | 31.0 (-29–65)               | 0.152   |
| MoCD11b, RFU 126 (72–297), n = 63                  | 284 (118–770)        | 337 (136–673)          | 0.953   | -91.5 (-290–123)        | -76.5 (-348–114)           | 0.877   | -35.0 (-301–445)         | -15.0 (-497–150)            | 0.349   |
| MoCD14, RFU 206 (74–379), n = 64                   | 161 (87–306)         | 186 (96.0–294)         | 0.626   | -28.5 (-115–68)         | -21.5 (-142–58)           | 0.797   | -5.00 (-75–19)           | -59.5 (-119–60)             | 0.173   |
| PMNCD11b, RFU 130 (75–466), n = 63                 | 324 (172–791)        | 325 (161–519)          | 0.861   | -50.5 (-426–236)        | -66.0 (-219–164)          | 0.918   | -37.0 (-215–242)         | -74.0 (-346–89)             | 0.173   |
| MoCD62L, RFU 118 (63–279), n = 64                  | 217 (133–313)        | 216 (87–343)           | 0.892   | -65.5 (-208–15)         | -68.0 (-226–18)           | 0.979   | -95.5 (-212–11)          | -109 (-212–8)               | 0.481   |
| PMNCD62L, RFU 131 (85–193), n = 64                 | 123 (40–239)         | 164 (78–227)           | 0.264   | -46.0 (-212–43)         | -67.5 (-123–25)           | 0.898   | -76.0 (-165–69)          | -80.0 (-165–65)             | 0.251   |

Mo: monocyte; PMN: neutrophil; RFU: relative fluorescence units.
The expressions of CD11b and CD62L were measured as markers of neutrophil activation. The expressions of CD11b and CD62L (Figure 2) of all patients were both downregulated during the first five days of follow-up period (PMNCD11b day 0: 325 RFU versus day 5: 259 RFU, $P = 0.001$; neutrCD62L day 0: 146 RFU versus day 5: 81 RFU, $P = 0.001$). The APC treatment did not have any effect on the changes in CD11b or CD62L expression on PMN cells between days 0 and 5 (Table 3).

4. Discussion

The results show that recombinant APC (drotrecogin alfa activated) treatment of patients with SAP did not alter the course of systemic inflammation, as determined using soluble and cellular markers of systemic inflammatory response. This is in accordance with the clinical findings of these patients, which indicated that SOFA score changes, organ-failure-free days, ICU or hospital stay time, ventilator-free days, renal replacement therapy-free days, vasopressor-free days, or days alive outside hospital (in 60 days) were comparable between APC and placebo groups [24]. The overall decreasing tendency of cytokines during the followup resembles earlier results, which show that both pro- and anti-inflammatory bursts are an early phenomenon in severe AP [15].

Several in vitro and animal studies show that APC has an anti-inflammatory activity. Administration of APC has been shown to downregulate the expression of inflammatory cytokines and chemokines. APC blocks cytokine production from Th2 lymphocytes [26]. APC has been shown to reduce production of endotoxemia-induced proinflammatory cytokines (IL-6, IL-8, IL-1beta, and TNF alfa) [27]. In vitro the production of IL-8 from monocytes is inhibited by APC (LPS-stimulated THP-1 cells) [28]. In vitro APC has been shown to inhibit chemotaxis and IL-6 release by human neutrophils [29]. APC inhibits TNF-alpha production by blocking nuclear factor (NF) kB transcription factor in monocytes [30]. APC has been shown to upregulate anti-inflammatory mediators, like IL-10 in blood monocytes in patients with severe sepsis [31]. APC can also block leukocyte trafficking by decreasing the expression of adhesion molecules (ICAM-1, E-selectin, and VCAM-1) on the endothelium [32–35].

Several clinical trials have been established to evaluate the APC treatment in sepsis patients. In the PROWESS trial they found that recombinant human activated protein C (drotrecogin alfa) reduced mortality in patients with severe sepsis [36]. In this randomized multicentre trial they found decreases in D-dimer levels and IL-6 levels in patients’ plasma that has been taken as evidence of anti-inflammatory action of APC [23]. HLA-DR expression, as marker of immunosuppression, has been shown to correlate with PC and APC levels in SAP [22]. Preliminary, still unpublished results from the PROWESS-SHOCK trial indicated that APC did not have a beneficial effect on 28-day survival in patients with septic shock.
No previous randomized trial has scrutinized the effect of APC in SAP patients, nor is there such evidence of APC’s effect on inflammation in SAP. The present study of phlogistic markers supports the view that APC treatment does not affect either the course of systemic inflammation in agreement with no detected effect on organ dysfunction [24].

Limitations of the study. The sample size for the study (16 + 16) was determined according to the primary end point and not for comparing systemic inflammatory response between the groups. In addition the number of follow-up samples/patients was decreased at day five (12 + 14) and at day 14 (11 + 10); therefore it is not possible to exclude a type II error.

5. Conclusion

The recombinant APC (drotrecogin alfa activated) treatment of patients with SAP did not alter the course of systemic inflammation, as determined using soluble and cellular markers of systemic inflammation.

Abbreviation

APCAP: Activated protein C in acute pancreatitis
AP: Acute pancreatitis
SAP: Severe acute pancreatitis
PC: Protein C
APC: Activated protein C
PCT: Procalcitonin
OD: Organ dysfunction
SOFA: Sequential organ failure assessment
EIA: Enzyme immuno assays
RFU: Relative fluorescence units
ICU: Intensive care unit
PROWESS: Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis.

Acknowledgments

The study was supported by grants from Helsinki University Central Hospital Research funds, Helsinki, Finland and the Competitive Research Funding of Tampere University Hospital, Tampere, Finland.

References

[1] J. M. Grönroos and E. I. Nylamo, “Mortality in acute pancreatitis in Turku University Central Hospital 1971–1995,” Hepato-Gastroenterology, vol. 46, no. 28, pp. 2572–2574, 1999.
[2] R. Mofidi, K. K. Madhavan, O. J. Garden, and R. W. Parks, “An audit of the management of patients with acute pancreatitis against national standards of practice,” British Journal of Surgery, vol. 94, no. 7, pp. 844–848, 2007.
[3] J. E. Repine, “Scientific perspectives on adult respiratory distress syndrome,” The Lancet, vol. 339, no. 8791, pp. 466–469, 1992.
[4] B. Rau, G. Steinbach, F. Gansauge, J. M. Mayer, A. Grünert, and H. G. Beger, “The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis,” Gut, vol. 41, no. 6, pp. 832–840, 1997.
[5] E. Aoun, J. Chen, D. Reighard, F. C. Gleeson, D. C. Whitcomb, and G. I. Papachristou, “Diagnostic accuracy of interleukin-6 and interleukin-8 in predicting severe acute pancreatitis: a meta-analysis,” Pancreatology, vol. 9, no. 6, pp. 777–785, 2010.
[6] D. Štimac, E. Fisić, S. Milić, L. Bilić-Zulle, and R. Perić, “Prognostic values of IL-6, IL-8, and IL-10 in acute pancreatitis,” Journal of Clinical Gastroenterology, vol. 40, no. 3, pp. 209–212, 2006.
[7] J. Mayer, B. Rau, F. Gansauge, and H. G. Beger, “Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications,” Gut, vol. 47, no. 4, pp. 546–552, 2000.
[8] M. Hynninen, M. Valtonen, H. Markkanen et al., “Interleukin 1 receptor antagonist and E-selectin concentrations: a comparison in patients with severe acute pancreatitis and severe sepsis,” Journal of Critical Care, vol. 14, no. 2, pp. 63–68, 1999.
[9] P. Mentula, M.-L. Kylänpää, E. Kemppainen et al., “Plasma anti-inflammatory cytokines and monocyte human leucocyte antigen-DR expression in patients with acute pancreatitis,” Scandinavian Journal of Gastroenterology, vol. 39, no. 2, pp. 178–187, 2004.
[10] M. L. Kylänpää–Bäck, A. Takala, E. A. Kemppainen et al., “Procalcitonin, soluble interleukin-2 receptor, and soluble E-selectin in predicting the severity of acute pancreatitis,” Critical Care Medicine, vol. 29, no. 1, pp. 63–69, 2001.
[11] J. J. Powell, A. K. Siriwardena, K. C. H. Fearon, and J. A. Ross, “Endothelial-derived selects in the development of organ dysfunction in acute pancreatitis,” Critical Care Medicine, vol. 29, no. 3, pp. 567–572, 2001.
[12] R. Pezzilli, M. M. Corsi, A. Barassi et al., “Serum adhesion molecules in acute pancreatic: time course and early assessment of disease severity,” Pancreas, vol. 37, no. 1, pp. 36–41, 2008.
[13] M.-L. Kylänpää–Bäck, A. Takala, E. Kemppainen et al., “Cytokines of systemic inflammation and immune suppression in patients with organ failure due to severe acute pancreatitis,” Scandinavian Journal of Gastroenterology, vol. 36, no. 10, pp. 1100–1107, 2001.
[14] S. H. Rahman, C. S. Verbeke, D. Gomez, M. J. McMahon, and K. V. Menon, “Pancreatitu-duodenectomy for complicated groove pancreatitis,” HPB, vol. 9, no. 3, pp. 229–234, 2007.
[15] P. Mentula, M. L. Kylänpää–Bäck, E. Kemppainen et al., “Decreased HLA (human leucocyte antigen)-DR expression on peripheral blood monocytes predicts the development of organ failure in patients with acute pancreatitis,” Clinical Science, vol. 105, no. 4, pp. 409–417, 2003.
[16] A. Richter, T. Nebe, K. Wendt et al., “HLA-DR expression in acute pancreatitis,” European Journal of Surgery, vol. 165, no. 10, pp. 947–951, 1999.
[17] L. J. Toldl, R. C. Austin, and P. C. Liaw, “Activated protein C modulates inflammation, apoptosis and tissue factor procoagulant activity by reculating endoplasmic reticulum calcium depletion in blood monocytes,” Journal of Thrombosis and Haemostasis, vol. 9, pp. 582–592, 2010.
[18] C. T. Esmon, “The protein C anticoagulant pathway,” Arteriosclerosis and Thrombosis, vol. 12, no. 2, pp. 135–145, 1992.
[19] J. Xu, N. L. Esmon, and C. T. Esmon, “Reconstitution of the human endothelial cell protein C receptor with thrombomodulin in phosphatidylcholine vesicles enhances protein C activation,” The Journal of Biological Chemistry, vol. 274, no. 10, pp. 6704–6710, 1999.
[20] P. P. Sarangi, H. W. Lee, and M. Kim, “Activated protein C action in inflammation,” British Journal of Haematology, vol. 148, no. 6, pp. 817–833, 2010.
[21] M. Levi and H. Ten Cate, “Disseminated intravascular coagulation,” The New England Journal of Medicine, vol. 341, no. 8, pp. 586–592, 1999.

[22] O. Lindstrom, L. Kylanpaa, P. Mentula et al., “Upregulated but insufficient generation of activated protein C is associated with development of multiorgan failure in severe acute pancreatitis,” Critical Care, vol. 10, no. 1, article R16, 2006.

[23] G. R. Bernard, J.-L. Vincent, P.-F. Laterre et al., “Efficacy and safety of recombinant human activated protein C for severe sepsis,” The New England Journal of Medicine, vol. 344, no. 10, pp. 699–709, 2001.

[24] V. Pettila, L. Kyhala, M. L. Kylanpaa et al., “APCAP—activated protein C in acute pancreatitis: a double-blind randomized human pilot trial,” Critical Care, Article ID R139, 2010.

[25] S. M. Opal and V. A. DePalo, “Anti-inflammatory cytokines,” Chest, vol. 117, no. 4, pp. 1162–1172, 2000.

[26] H. Yuda, Y. Adachi, O. Taguchi et al., “Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice,” Blood, vol. 103, no. 6, pp. 2196–2204, 2004.

[27] K. Okajima, “Regulation of inflammatory responses by natural anticoagulants,” Immunological Reviews, vol. 184, pp. 258–274, 2001.

[28] D. A. Stephenson, L. J. Toltl, S. Beaudin, and P. C. Liaw, “Modulation of monocyte function by activated protein C, a natural anticoagulant,” Journal of Immunology, vol. 177, no. 4, pp. 2115–2122, 2006.

[29] H. F. Galley, N. E. El Sakka, N. R. Webster, D. A. Lowes, and B. H. Cuthbertson, “Activated protein C inhibits chemotaxis and interleukin-6 release by human neutrophils without affecting other neutrophil functions,” British Journal of Anaesthesia, vol. 100, no. 6, pp. 815–819, 2008.

[30] M. Yuksel, K. Okajima, M. Uchiba, S. Horiuchi, and H. Okabe, “Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-α production by inhibiting activation of both nuclear factor-κB and activator protein-1 in human monocytes,” Thrombosis and Haemostasis, vol. 88, no. 2, pp. 267–273, 2002.

[31] L. J. Toltl, S. Beaudin, P. C. Liaw et al., “Activated protein C upregulates IL-10 and inhibits tissue factor in blood monocytes,” Journal of Immunology, vol. 181, no. 3, pp. 2165–2173, 2008.

[32] B. W. Grinnell, B. Gerlitz, and D. T. Berg, “Identification of a region in protein C involved in thrombomodulin-stimulated activation by thrombin: potential repulsion at anion-binding site I in thrombin,” Biochemical Journal, vol. 303, part 3, pp. 929–933, 1994.

[33] D. E. Joyce, L. Gelbert, A. Ciaccia, B. DeHoff, and B. W. Grinnell, “Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis,” The Journal of Biological Chemistry, vol. 276, no. 14, pp. 11199–11203, 2001.

[34] J. A. Nick, C. D. Coldren, M. W. Geraci et al., “Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis,” Blood, vol. 104, no. 13, pp. 3878–3885, 2004.

[35] D. H. Sturn, N. C. Kaneider, C. Feistritzer, A. Djanani, K. Fukudome, and C. J. Wiedermann, “Expression and function of the endothelial protein C receptor in human neutrophils,” Blood, vol. 102, no. 4, pp. 1499–1505, 2003.

[36] G. R. Bernard, E. W. Ely, T. J. Wright et al., “Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis,” Critical Care Medicine, vol. 29, no. 11, pp. 2051–2059, 2001.